文献速递抗栓抗凝管理特殊人群用药

药物干预预防胎儿生长受限:系统综述与网络荟萃分析

Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Clin Pharmacol Ther · 2021-02-26

结果显示,低分子肝素(LMWH)单用或联用低剂量阿司匹林(LDA)在预防FGR方面似乎优于对照,未见治疗增加出血风险。

要点

  • LMWH单用或联用LDA预防FGR可能优于安慰剂或不治疗。
  • 各活性治疗之间在预防FGR上未见差异,但除LMWH±LDA外估计不精确。
  • 仅LMWH与对照比较的证据置信度被评为中等,未见治疗增加出血风险。

核心结论

  • LMWH单用或联用LDA在预防FGR方面似乎比对照更有效,但除LMWH±LDA外其他治疗的估计不精确。
  • 仅LMWH与对照比较的证据置信度根据CINeMA框架被评为中等。
  • 没有治疗与出血风险增加相关,但仅LMWH的估计足够精确。

研究设计与样本

  • 纳入30项研究共4326例单胎妊娠女性,包括临床试验和观察性研究。
  • 采用频率学框架网络荟萃分析,计算比值比(OR)和95%置信区间(CI)。

主要发现

  • 对照 vs. LMWH预防FGR的OR为2.00(95% CI 1.27-3.16)。
  • 对照 vs. LDA+LMWH预防FGR的OR为2.67(95% CI 1.21-5.89)。
  • 各活性治疗之间在FGR预防上未见差异,但除LMWH±LDA外估计不精确。
  • 没有治疗与出血风险增加相关,但仅LMWH的估计足够精确。

临床怎么用

  • 结果可为临床医生提供FGR预防中活性药物预防获益的信息。
  • LMWH单用或联用LDA可能作为FGR预防的考虑选项,但需结合证据置信度中等判断。

局限性

  • 除LMWH±LDA外,其他治疗的估计不精确。
  • 仅LMWH与对照比较的证据置信度被评为中等。
  • 出血风险估计仅对LMWH足够精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevention of fetal growth restriction (FGR) is challenging in clinical practice. To date, no meta-analysis summarized evidence on the relative benefits and harms of pharmacological interventions for FGR prevention. We performed a systematic review and network meta-analysis (NetMA), searching PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from inception until November 2019. We included clinical trials and observational studies on singleton gestating women evaluating antiplatelet, anticoagulant, or other treatments, compared between each other or with controls (placebo or no treatment), and considering the pregnancy outcome FGR (primary outcome of the NetMA). Secondary efficacy outcomes included preterm birth, placental abruption, and fetal or neonatal death. Safety outcomes included bleeding and thrombocytopenia. Network meta-analyses using a frequentist framework were conducted to derive odds ratios (ORs) and 95% confidence intervals (CIs). Of 18,780 citations, we included 30 studies on 4,326 patients. Low molecular weight heparin (LMWH), alone or associated with low-dose aspirin (LDA), appeared more efficacious than controls in preventing FGR (OR 2.00, 95% CI 1.27-3.16 and OR 2.67, 95% CI 1.21-5.89 for controls vs. LMWH and LDA + LMWH, respectively). No difference between active treatments emerged in terms of FGR prevention, but estimates for treatments other than LMWH +/- LDA were imprecise. Only the confidence in the evidence regarding LMWH vs. controls was judged as moderate, according to the Confidence in Network Meta-Analysis framework. No treatment was associated with an increased risk of bleeding, although estimates were precise enough only for LMWH. These results should inform clinicians on the benefits of active pharmacological prophylaxis for FGR prevention.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bettiol A, Avagliano L, Lombardi N, et al. Pharmacological Interventions for the Prevention of Fetal Growth Restriction: A Systematic Review and Network Meta-Analysis. Clin Pharmacol Ther. 2021. PMID: 33423282. doi:10.1002/cpt.2164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。